Data show that 65 percent of participants demonstrated the maximal improvement in the clinical trial’s primary endpoint, bilateral multi-luminance mobility testing (MLMT), at year one
Bpifrance and Foundation Fighting Blindness have launched SparingVision to develop vision-saving treatment for Inherited Retinal Diseases. The newly established French company, SparingVision has won the 2017 i-Lab Grand Prize recognizing new and innovative companies. The i-Lab competition is organized by the French Ministry of Higher Education, Research and Innovation and Bpifrance (BPI).
ProQR Therapeutics N.V. has announced that the company’s investigational drug QRX-411 has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype targeted by QRX-411. Usher syndrome is the leading cause of combined deafness and blindness due to genetic defects in the Usher gene.
Retina International is delighted to announce the appointment of Ms. Vicky McGrath to the position of Project Coordinator on a six month contract. Vicky will be working with the RI team and a coalition of global patient leaders from the retina, low vision and aging fields to develop and roll out an online Toolkit on Age-related Macular Degeneration.
Retina International is counting down to its World Congress 2018 which is now just eight months away! The RIWC takes place on the 10th and 11th of February 2018 in Auckland New Zealand.
This event will bring together some of the world’s foremost retinal scientists and clinicians along with the global leaders in patient advocacy and peer support. With a two day scientific programme covering the key developments in basic and clinical research as well as further information on therapeutic development it is an event not to be missed.
The 18th International Symposium on Retinal Degeneration will be held in Killarney, Co Kerry, Ireland on September 3-8, 2018. The venue is the Victorian Hotel ‘The Malton’ in Killarney town.
The Board of Directors and National Trustees of the Foundation Fighting Blindness (FFB ) are sharing a recent New York Times article featuring Gordon and Lulie Gund. The column, written by David Brooks, is focused on the power of philanthropy and the motivation of philanthropists. Being mentioned is a welcome and fitting tribute to the Gunds’ commitment to finding treatments and cures for inherited retinal disease (IRDs) through supporting research for more than four decades and it is also an opportunity to make more people aware of the work of FFB and its mission.
The Foundation Fighting Blindness (FFB) today announced $6 million in new research funding across a spectrum of potential preventions, treatments and cures for inherited retinal diseases including retinitis pigmentosa and macular degeneration. With this new funding, FFB now supports 101 research projects conducted by over 150 investigators at 61 institutions worldwide.
Retina France and Macula Retina Spain are pleased to announce the first Patient Congress on The Retina and Macula, which will take place in Seville, Spain on Friday 20th and Saturday 21st of October, 2017. This initiative was conceived In October 2016 by the team of Jacinto Zulueta of Macula Retina Spain and Retina France at an event organised by Retina International.
Picture: Lisbon, Portugal
For a blind traveller, I suggest venturing to Spain, Portugal and Morocco — lands of contrasting pleasures and unique curiosities.
Travelogue by Fraser Alexander, Retina New Zealand